spacer
home > directory > Arcis Biotechnology
PHARMACEUTICAL INDUSTRY DIRECTORY

Arcis Biotechnology

Arcis Biotechnology specializes in the rapid, innovative room temperature extraction and stabilization of nucleic acids from a wide range of biological samples from blood, to stool, tissue and even plant. The nucleic acids extracted using the Arcis technology are enhanced and protected from inhibitors so that they can be directly used in quantitative Polymerase Chain Reaction (qPCR), Reverse-Transcription Polymerase Chain Reaction (RT-qPCR), Isothermal Amplification (LAMP) and even Next Generation Sequencing without any further purification being required. This ability to perform a fast three-minute extraction and go directly into downstream nucleic acid processing enables greatly expedited workflows.

Our kits are especially suited to point of care extraction of DNA and RNA, as they require no specialist equipment, centrifugation or heating and the extraction can be completed with two simple pipetting steps. The kits are also designed to instantly stabilize the nucleic acids in samples for up to 90 days at room temperature allowing precious samples to be preserved or shipped. This instant stabilization makes the Arcis technology especially suited to preservation of fragile mRNA and miRNA making Arcis kits a good choice for expression analysis, anti-biotic efficacy studies and biomarker studies.

Arcis manufactures and produces both Research Use Only Sample Preparation kits, and also CE-IVD validated Blood and Pathogen extraction kits at a range of scales from one off bench testing to high throughput kits suitable for the automated processing of multiple samples. Our in-house manufacturing capabilities mean that we can on request provide bespoke kits to fit in with specific chemistries or workflows or offer OEM solutions for individual customer needs.

Arcis QMS is ISO13485 accredited, this ensures that products satisfy the requirements of regulators and customers alike and commitment to continuous improvements in product safety, quality and performance. Manufacturing facilities operate under the framework of ISO13485 and FDA 21 CFR Part 820. This ensures that all aspects of product realisation are consistently checked and improved to deliver high-quality products every time. In-process QC checks ensure that products are on-spec during dispense with every step verified by trained, experienced operators. Finished goods are QC tested to verify that Arcis products meet our stringent performance requirements. All aspects of the supply chain are carefully controlled to guarantee that end-users will receive the best performing products in the best condition, furthermore, all Arcis business processes are guided by ISO14971, ensuring safety and efficiency in all areas.

Our products have proved particularly attractive to scientists wishing to rapidly detect pathogen- bacterial, pseudomonas, fungal or viral- including but not limited to MRSA, Escherichia coli, Sepsis, Candida, Aspergillus, Malaria and Zika. Pathogen nucleic acid extraction has been shown to be effective from both cultured samples and directly from human samples such as blood, buccal swabs, stool or urine. The Arcis nucleic acid extraction technology can be applied to molecular biology testing for many different applications including food safety, oncology, human and vet pathogen diagnostics and environmental testing. The Arcis Sample Preparation technology is compatible with most commercially available qPCR master mixes and library preparation kits.
phone 01925 607100
email info@arcisbio.com
web www.arcisbio.com
email Arcis Biotechnology Limited, The Innovation Centre, Sci-tech Daresbury, Keckwick Lane, Daresbury, Cheshire, WA4 4FS, UK
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 
News and Press Releases

Signant Health Appoints Todd Everhart as Clinical Vice President to Accelerate Intelligent eCOA and Predictive Data Analytics in Medical Clinical Research

PHILADELPHIA, PA August 20, 2019: Signant Health, formerly CRF Health and Bracket, has appointed Anthony Todd Everhart, MD, FACP to the Signant Health Science and Medicine Team as Clinical Vice President, Internal Medicine, reporting to the Chief Medical Officer, Dr. David Daniel.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement